首页> 外文期刊>Cancer Medicine >Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo
【24h】

Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo

机译:肾上腺髓质素在人大肠肿瘤中的表达及其在体外和体内细胞生长和侵袭中的作用

获取原文
           

摘要

AbstractAdrenomedullin (AM) is a multifunctional peptide vasodilator that transduces its effects through calcitonin receptor-like receptor/receptor activity-modifying protein-2 and -3 (CLR/RAMP2 and CLR/RAMP3). In this study, real-time quantitative reverse transcription demonstrated a significant expression of AM mRNA in tumor samples from colorectal cancer (CRC) patients in clinical stage II, III, and IV when compared with normal colorectal tissue. AM, CLR, RAMP2, and RAMP3 proteins were immunohistochemically localized in the carcinomatous epithelial compartment of CRC tissue. Tissue microarray analysis revealed a clear increase of AM, CLR, RAMP2, and RAMP3 staining in lymph node and distant metastasis when compared with primary tumors. The human colon carcinoma cells HT-29 expressed and secreted AM into the culture medium with a significant increase under hypoxia. Treatment of HT-29 cells with synthetic AM stimulated cell proliferation and invasion in vitro. Incubation with anti-AM antibody (αAM), anti-AM receptors antibodies (αAMR), or AM antagonist AM22–52 inhibited significantly basal levels of proliferation of HT-29 cells, suggesting that AM may function as an autocrine growth factor for CRC cells. Treatment with αAM significantly suppressed the growth of HT-29 tumor xenografts in vivo. Histological examination of αAM-treated tumors showed evidence of disruption of tumor vascularity with decreased microvessel density, depletion of endothelial cells and pericytes, and increased tumor cell apoptosis. These findings highlight the potential importance of AM and its receptors in the progression of CRC and support the conclusion that αAM treatment inhibits tumor growth by suppression of angiogenesis and tumor growth, suggesting that AM may be a useful therapeutic target.
机译:摘要肾上腺髓质素(AM)是一种多功能肽血管扩张剂,可通过降钙素受体样受体/受体活性修饰蛋白2和-3(CLR / RAMP2和CLR / RAMP3)传递其作用。在这项研究中,实时定量逆转录证明与临床结直肠组织相比,在临床II,III和IV期大肠癌(CRC)患者的肿瘤样品中AM mRNA的表达显着。将AM,CLR,RAMP2和RAMP3蛋白免疫组化定位在CRC组织的癌性上皮区室中。组织微阵列分析显示与原发性肿瘤相比,淋巴结和远处转移中AM,CLR,RAMP2和RAMP3染色明显增加。在低氧条件下,人结肠癌细胞HT-29在培养基中表达并分泌AM,并显着增加。用合成AM处理HT-29细胞可刺激体外细胞增殖和侵袭。与抗AM抗体(αAM),抗AM受体抗体(αAMR)或AM拮抗剂AM 22–52 一起孵育可显着抑制HT-29细胞的基础增殖水平,这表明AM可能起作用作为CRC细胞的自分泌生长因子。用αAM处理可显着抑制体内HT-29肿瘤异种移植物的生长。对经αAM治疗的肿瘤的组织学检查显示,微血管密度降低,内皮细胞和周细胞耗竭以及肿瘤细胞凋亡增加,破坏了肿瘤血管。这些发现突出了AM及其受体在CRC进展中的潜在重要性,并支持αAM治疗通过抑制血管生成和肿瘤生长来抑制肿瘤生长的结论,表明AM可能是有用的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号